Antithrombotic therapy in atrial fibrillation: Ximelagatran, an oral direct thrombin inhibitor

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 2, 2004, Pages 163-174

  Halperin, Jonathan L ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Melagatran; Stroke; Thromblin; Thromboembolism; Warfarin; Ximelegatran

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DIAZEPAM; DICLOFENAC; FLUCLOXACILLIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LB 30057; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; N (9 HYDROXY 9 FLUORENECARBOXY)PROLINE (4 AMINOCYCLOHEXYLMETHYL)AMIDE; NIFEDIPINE; PLACEBO; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; GALLSTONE; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HEMOPERICARDIUM; HEPATITIS B; HUMAN; INTERNATIONAL STANDARD UNIT; JAUNDICE; LIVER DYSFUNCTION; LIVER METASTASIS; RETROPERITONEAL HEMORRHAGE; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HUMANS; PRODRUGS; RANDOMIZED CONTROLLED TRIALS; THERAPEUTIC EQUIVALENCY; THROMBOEMBOLISM; WARFARIN;

EID: 2642540983     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.2.163     Document Type: Review

References (92)

1. Murray CJL, Lopez AD, Mathers CD, Stein C. The global burden of disease 2000 project: aims, methods and data sources. Global Programme on Evidence for Health Policy -Discussion Papers, No. 36. Geneva, World Health Organization (2001).
2. Atrial fibrillation as a contributing cause of death and Medicare hospitalization - United States, 1999. MMWR 52, 128-131 (2003).
3. Public health and aging: hospitalizations for stroke among adults aged 65 years or over - United States, 2000. MMWR 52, 586-589 (2003).
4. American Heart Association. Heart disease and stroke statistics - 2003 update (2002).
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983-988 (1991).
6. Falk RH. Atrial fibrillation. N. Engl. J. Med. 344, 1067-1078 (2001).
7. Conway DS, Heeringa J, Van Der Kuip DA et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 34, 413-417 (2003).
8. Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. Can. Med. Assoc. J. 157, 673-681 (1997).
9. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107, 3141-3145 (2003).
10. EAFT (European Atrial Fibrillation Trial Study Group). Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342, 1255-1262 (1993).
11. Albers GW, Dalen JE, Laupacis A et al. Antithrombotic therapy in atrial fibrillation. Chest 119, 194S-206S (2001).
12. Karatas M, Dilek A, Erkan H et al. Functional outcome in stroke patients with atrial fibrillation. Arch. Phys. Med. Rehabil. 81, 1025-1029 (2000).
13. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 22, 118-123 (2003).
14. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 33, 2722-2727 (2002).
15. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. 155, 469-473 (1995).
16. de Craen AJ, Gussekloo J, Teng YK, Macfarlane PW, Westendorp RG. Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study. Br. Med. J. 327, 131-132 (2003).
17. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108, 711-716 (2003).
18. United Nations. World Population Prospects. The 2002 Revision. ESA/P/WP.165. United Nations, NY, USA (2001).
19. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J. Am. Coll. Cardiol. 42, 93-100 (2003).
20. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 22, 1852-1923 (2001).
21. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98, 946-952 (1998).
22. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449-1457 (1994).
23. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131, 492-501 (1999).
24. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 119, S8-S21 (2001).
25. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. 78, 1286-1292 (1997).
26. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. 94, 187-197 (1999).
27. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121, 676-683 (1994).
28. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
29. Tabrizi AR, Zehnbauer BA, Borecki IB et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. 194, 267-273 (2002).
30. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 119, S108-S121 (2001).
31. Hylek EM, Regan S, Go AS et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann. Intern. Med. 135, 393-400 (2001).
32. Ansell J, Hirsh J, Dalen J et al. Managing oral anticoagulant therapy. Chest 119, S22-S38 (2001).
33. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349, 1019-1026 (2003).
34. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med. 160, 41-46 (2000).
35. Antani MR, Beyth RJ, Covinsky KE et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J. Gen. Intern. Med. 11, 713-720 (1996).
36. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch. Intern. Med. 154, 1945-1953 (1994).
37. Gurwritz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch. Intern. Med. 157, 978-984 (1997).
38. Malik AK, Taylor AJ. Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. South Med. J. 93, 58-61 (2000).
39. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 119, S95-S107 (2001).
40. Abraham E, Reinhart K, Svoboda P et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med. 29, 2081-2089 (2001).
41. Lee A, Agnelli G, Buller H et al. Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104, 74-78 (2001).
42. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345, 1305-1310 (2001).
43. Dyke CK, Becker RC, Kleiman NS et al. First experience with direct Factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 105, 2385-2391 (2002).
44. Wong PC, Quan ML, Crain EJ et al. Nonpeptide Factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J. Pharmacol. Exp. Ther. 292, 351-357 (2000).
45. Taniuchi Y, Sakai Y, Hisamichi N et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally-active inhibitor of human Factor Xa. Thromb. Haemost. 79, 543-548 (1998).
46. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119, S64-S94 (2001).
47. Gonze MD, Manord JD, Leone-Bay A et al. Orally administered heparin for preventing deep venous thrombosis. Am. J. Surg. 176, 176-178 (1998).
48. Gonze MD, Salartash K, Sternbergh WC III et al. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 101, 2658-2661 (2000).
49. Pineo GF, Hull RD, Marder VJ. Orally-active heparin and low-molecular-weight heparin. Curr. Opin. Pulm. Med. 7, 344-348 (2001).
50. Eriksson BI, Wille-Jorgensen P, Kalebo P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. 337, 1329-1335 (1997).
51. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin. Hematol. 35, 26-34 (1998).
52. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838-1843 (2001).
53. Kathiresan S, Shiomura J, Jang IK. Argatroban. J. Thromb. Thrombolysis 13, 41-47 (2002).
54. Brady SF, Stauffer KJ, Lumma WC et al. Discovery and development of the novel potent orally-active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J. Med. Chem. 41, 401-406 (1998).
55. McClanahan TB, Hicks GW, Ignasiak DP et al. The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. J. Thromb. Thrombol. 10, 277-284 (2000).
56. Oh YS, Yuri M, Hwang SY et al. Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorg. Med. Chem. Lett. 8, 631-634 (1998).
57. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr. Opin. Investig. Drugs 3, 905-907 (2002).
58. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 254, 322-334 (2003).
59. Colwell CW, Berkowitz SD, Davidson BL et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism, following total hip replacement. A randomized, double-blind study. J. Thromb. Haemost. 1, 2119-2130 (2003).
60. Eriksson BI, Bergqvist D, Kalebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360, 1441-1447 (2002).
61. Eriksson BI, Agnelli G, Cohen AT et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb. Haemost. 89, 288-296 (2003).
62. Francis CW, Davidson BL, Berkowitz SD et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. 137, 648-655 (2002).
63. Eriksson BI, Agnelli G, Cohen AT et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost. 1(12), 2490-2496 (2003).
64. Heit JA, Colwell CW, Francis CW et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a Phase II dose-finding study. Arch. Intern. Med. 161, 2215-2221 (2001).
65. Francis CW, Berkowitz SD, Comp PC et al. Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. N. Engl. J. Med. 349, 1703-1712 (2003).
66. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789-797 (2003).
67. Halperin JL and the Executive Steering Committee on behalf of the SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart. J. 146, 431-438 (2003).
68. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability and safety study. J. Am. Coll. Cardiol. 41, 1445-1451 (2003).
69. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvularatrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
70. Wolzt M, Wollbratt M, Svensson M, Wahlander K, Grind M, Eriksson UG. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur. J. Clin. Pharmacol. 59, 537-543 (2003).
71. Gustafsson D, Nystrom J, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101, 171-181 (2001).
72. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res. 109(Suppl. 1), S9-S15 (2003).
73. Boström SL, Hansson GF, Kjaer M, Sarich TC. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran and dalteparin on the endogenous thrombolin potential in venous blood from healthy male subject. Blood Coagul. Fibrinolysis 14, 457-462 (2003).
74. Sarich TC, Eriksson UG, Mattsson C et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb. Haemost. 87, 300-305 (2002).
75. Eriksson UG, Bredberg U, Gislen K et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur. J. Clin. Pharmacol. 59, 35-43 (2003).
76. Sarich TC, Wolzt M, Eriksson UG et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J. Am. Coll. Cardiol. 41, 557-564 (2003).
77. Johansson LC, Frison L, Logren U et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokin. 42, 381-392 (2003).
78. Johansson L, Andersson M, Fager G, Gustafsson D, Eriksson U. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin. Pharmacokinet. 42, 475-484 (2003).
79. Sarich TC, Teng R, Peters GR et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin. Pharmacokinet. 42, 485-492 (2003).
80. Wolzt M, Boström SL, Svensson M et al. Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation. Pathophysiol. Haemost. Thromb. 33, 68-74 (2003).
81. Bredberg E, Andersson TB, Frison L et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin. Pharmacokinet. 42, 765-777 (2003).
82. Johansson S, Schützer K-M, Kessler E, Eriksson UG. No influence of alcohol intake on the pharmacokinetics or pharmacodynamics of the oral direct thrombin inhibitor, ximelagatran, in healthy volunteers. J. Thromb. Haemost. 1, 1991 (2003).
83. Teng R, Sarich TC, Eriksson UG et al. No clinically significant interaction between ximelagatran, an oral direct thrombin inhibitor and amiodarone. Eur. Heart J. (2003) (In Press).
84. Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur. J. Clin. Pharmacol. 59, 283-289 (2003).
85. Eriksson UG, Johansson S, Attman PO et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and sc. melagatran. Clin. Pharmacokin. 42, 743-753 (2003).
86. Eriksson U, Mandema J, Karlsson M et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving sc. melagatran and oral ximelagatran: a population model analysis. Clin. Pharmacokinet. 42, 687-701 (2003).
87. Eriksson UG, Bååthe S, Hamrén B et al. Predictable pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in nonvalvular atrial fibrillation patients receiving long-term treatment. Pathophysiol Haemost. Thromb. 32, 56 (2002).
88. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B for the Copenhagen AFASAK study. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1, 175-179 (1989).
89. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84, 527-539 (1991).
90. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323, 1505-1511 (1990).
91. Petersen P. A 2-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Neurology 58, A477 (2002).
92. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Intern. Med. 131, 927-934 (1999).